Since the FDA approval for Sarepta's Exondys 51 (eteplirsen) , the stock is down ~ 50% from those highs. Now that it is range-bound, speculators should consider this stock again. $SRPT, Sarepta Therapeutics, Inc. / D In April, the CEO stepped down, fuelling speculation of a buyout.At prices below $30/share, SRPT is ripe for a take-out.Buy SRPT. Agree or disagree?Login via StockTwits and vote!